Series A: e-Books on Cardiovascular Diseases
Series A Content Consultant: Justin D Pearlman, MD, PhD, FACC
VOLUME TWO
Cardiovascular Original Research:
Cases in Methodology Design for Content Co-Curation
The Art of Scientific & Medical Curation
http://www.amazon.com/dp/B018Q5MCN8
Justin D Pearlman, MD, PhD, FACC
Larry H Bernstein, MD, FCAP
and
Aviva Lev-Ari, PhD, RN
Introduction to Volume Two
Part 1: The Methodology of Curation for Scientific Research Findings
1.1 The Methodology Explained
1.1.1 Curation by a Single Curator
1.1.2 Co-Curation by Several Experts, Authors, Writers
1.1.3 Editor’s Curation of an electronic Table of Contents (eTOCs) of an e-Book or a Hardcover Volume
1.2 The Creation Process of a Curation as an Alternative Model for Scientific Publishing
1.3 FIVE steps in the Creation Process of a Curation
1.3.1 CURATION and Co-CURATION of Scientific articles in conjunction with Experts, Authors, Writers critique and synthesis
1.3.2 Assembly of articles into e-Books using ONE of a Kind electronic Table of Contents (eTOCs) architecture
1.3.3 Assembly of e-Books into e-Series
1.3.4 Publishing of e-Series on Amazon.com
1.3.5 Distribution of e-Series to Professional Associations via their Internet website
1.4 Other Alternative Types to the Academic Publishing Model
1.5 Methodology of Curation Applied to Medical Research Findings
1.5.1 The Voice of Content Consultant on The Methodology of Curation
1.5.2 Curation is Uniquely Distinguished by the Historical Exploratory Ties that Bind
Part 2: Cardiovascular Disease – Predicted Cost of Care and the
Affordable Care Act
Introduction
2.1 Cost of Care for Cardiovascular Medical Diagnoses
2.1.1 Diagnosis of Cardiovascular Disease, Treatment and Prevention: Current & AHA Predicted Cost of Care and the Promise of Individualized Medicine Using Clinical Decision Support Systems
2.1.2 Economic Toll of Heart Failure in the US: Forecasting the Impact of Heart Failure in the United States – A Policy Statement From the American Heart Association
2.1.3 Heart Disease: Economic and Personal Effects
2.2 Impact of 2013 HealthCare Reform in the US
2.2.1 The Affordable Care Act: A Considered Evaluation. Part I. The legislative act (ACA) and the model for implementation (Insurance Gateways).
2.2.2 The Affordable Care Act: A Considered Evaluation. Part II: The Implementation of the ACA, Impact on Physicians and Patients, and the Dis-Ease of the Accountable Care Organizations.
2.2.3 The Affordable Care Act: A Considered Evaluation. Part III. Final Implementation of the Affordable Care Act and a Patient and Community Outcomes Focus
2.2.4 Post Acute Care – Driver of Variation in Healthcare Costs
2.3 Patient Protection and Affordable Care Act Featured at RAND
Part 3: Causes of Cardiovascular Diseases
3.1 Human Genome: Congenital Etiological Sources of Cardiovascular Disease
3.1.1 Genomics & Genetics of Cardiovascular Disease Diagnoses
3.1.1.1 Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013
3.1.2 Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging
3.1.2.1 Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging
3.1.2.2 Transposon-mediated Gene Therapy improves Pulmonary Hemodynamics and attenuates Right Ventricular Hypertrophy: eNOS gene therapy reduces Pulmonary vascular remodeling and Arterial wall hyperplasia
3.1.3 Genetics of Conduction Disease
3.1.3.1 Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis
3.2 The Role of Calcium in Health and Disease
3.2.1 Identification of Biomarkers that are Related to the Actin Cytoskeleton – Part I
3.2.2 Role of Calcium, the Actin Skeleton, and Lipid Structures in Signaling and Cell Motility – Part II
3.2.3 Ca2+-Stimulated Exocytosis: The Role of Calmodulin and Protein Kinase C in Ca2+ Regulation of Hormone and Neurotransmitter
3.2.4 Disruption of Calcium Homeostasis: Cardiomyocytes and Vascular Smooth Muscle Cells: The Cardiac and Cardiovascular Calcium Signaling Mechanism – Part VIII
3.2.5 Synaptotagmin functions as a Calcium Sensor: How Calcium Ions Regulate the fusion of vesicles with cell membranes during Neurotransmission – Part X
3.2.6 The Centrality of Ca(2+) Signaling and Cytoskeleton Involving Calmodulin Kinases and Ryanodine Receptors in Cardiac Failure, Arterial Smooth Muscle, Post-ischemic Arrhythmia, Similarities and Differences, and Pharmaceutical Targets
3.2.7 Atherosclerosis Independence: Genetic Polymorphisms of Ion Channels Role in the Pathogenesis of Coronary Microvascular Dysfunction and Myocardial Ischemia (Coronary Artery Disease (CAD))
3.2.8 Calcium Signaling, Cardiac Mitochondria and Metabolic Syndrome
3.3 Vasculature and Myocardium: Diagnosing the Conditions of Disease
3.3.1 State of Cardiology on Wall Stress, Ventricular Workload and Myocardial Contractile Reserve: Aspects of Translational Medicine (TM)
3.3.2 Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus
3.3.3 Cardiovascular Complications: Death from Reoperative Sternotomy after prior CABG, MVR, AVR, or Radiation; Complications of PCI; Sepsis from Cardiovascular Interventions
3.3.4 Mitral Valve Repair: Who is a Patient Candidate for a Non-Ablative Fully Non-Invasive Procedure?
Part 4: Risks and Biomarkers for Cardiovascular Diseases
4.1 The Role of Calcium in Health and Disease
4.1.1 Renal Distal Tubular Ca2+ Exchange Mechanism in Health and Disease – Part III
4.2 Vasculature and Myocardium: Diagnosing the Conditions of Disease – Biomarkers of Acute Cardiovascular Events
4.2.1 No Early Symptoms – An Aortic Aneurysm Before It Ruptures – Is There A
Way To Know If I Have it?
4.2.2 Females and Non-Atherosclerotic Plaque: Spontaneous Coronary Artery Dissection: New Insights from Research and DNA Ongoing Study
4.2.3 Cardiovascular Diseases: Decision Support Systems for Disease
Management Decision Making
4.2.4 Dealing with the Use of the High Sensitivity Troponin (hs cTn) Assays
4.2.5 Prognostic Marker Importance of Troponin I in Acute Decompensated
Heart Failure (ADHF): Troponin I in acute decompensated heart failure:
insights from the ASCEND-HF study
4.2.6 More on the Performance of High Sensitivity Troponin T and with Amino
Terminal Pro BNP in Diabetes
4.2.7 The Cardio-Renal Syndrome (CRS) in Heart Failure (HF)
4.2.8 Vasoplegia in Orthotopic Heart Transplant Patients
4.2.9 Myocardial Infarction: The New Definition
After Revascularization
4.3 Biomarkers of Long Term Risk of Cardiovascular Disease
4.3.1 Special Considerations in Blood Lipoproteins, Viscosity, Assessment
and Treatment
4.3.2 What is the Role of Plasma Viscosity in Hemostasis and Vascular
Disease risk?
4.3.3 High-Density Lipoprotein (HDL): An Independent Predictor of
Endothelial Function & Atherosclerosis, A Modulator, An Agonist, A Biomarker
for Cardiovascular Risk
4.3.4 Artherogenesis: Predictor of CVD – the Smaller and Denser LDL
Particles
4.3.5 Hypertriglyceridemia concurrent Hyperlipidemia: Vertical Density
Gradient Ultracentrifugation a Better Test to Prevent Undertreatment of
High-Risk Cardiac Patients
4.3.6 Cholesteryl Ester Transfer Protein (CETP) Inhibitor: Potential of
Anacetrapib to treat Atherosclerosis and CAD
4.4 Conduction Dysfunction and ElectroPhysiology of the Heart
4.4.1 On Devices and On Algorithms: Arrhythmia after Cardiac Surgery Prediction and ECG Prediction of Paroxysmal Atrial Fibrillation Onset
4.4.2 Genetic Analysis of Atrial Fibrillation
4.4.3 Oxidized Calcium Calmodulin Kinase and Atrial Fibrillation
4.4.4 Renal Function Biomarker, β-trace protein (BTP) as a Novel Biomarker for Cardiac Risk Diagnosis in Patients with Atrial Fibrilation
4.5 Cardiovascular Imaging: Diagnosing the Condition of the Disease and Determining Course of Treatment
4.5.1 Imaging Biomarker for Arterial Stiffness: Pathways in Pharmacotherapy for Hypertension and Hypercholesterolemia Management
4.5.2 Coronary Circulation Combined Assessment: Optical Coherence Tomography(OCT), Near-Infrared Spectroscopy (NIRS) and Intravascular Ultrasound (IVUS) – Detection of Lipid-Rich Plaque and Prevention of Acute Coronary Syndrome (ACS)
4.5.3 Emerging Clinical Applications for Cardiac CT: Plaque Characterization,SPECT Functionality, Angiogram’s and Non-Invasive FFR
4.5.4 Fractional Flow Reserve (FFR) & Instantaneous wave-free ratio (iFR): An Evaluation of Catheterization Lab Tools (Software Validation) for Ischemic Assessment (Diagnostics) – Change in Paradigm: The RIGHT vessel not ALL vessel
4.5.5 Acute and Chronic Myocardial Infarction: Quantification of Myocardial Perfusion Viability – FDG-PET/MRI vs. MRI or PET alone
Part 5: Advances in Treatment of Cardiovascular Diseases
5.1 Vasculature and Myocardium: Diagnosing the Conditions of Disease
5.1.1 Erythropoietin (EPO) and Intravenous Iron (Fe) as Therapeutics for Anemia in Severe and Resistant CHF: The Elevated N-terminal proBNP Biomarker
5.1.2 Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO(rivaroxaban) or PRADAXA (dabigatran)
5.1.3 Alternative Designs for the Human Artificial Heart: The Patients in Heart Failure – Outcomes of Transplant (donor)/Implantation (artificial) and Monitoring Technologies for the Transplant/Implant Patient in the Community
5.1.4 Vascular Surgery: International, Multispecialty Position Statement on Carotid Stenting, 2013 and Contributions of a Vascular Surgeon at Peak Career – Richard Paul Cambria, MD
5.1.5 Heart Transplant (HT) Indication for Heart Failure (HF): Procedure Outcomes and Research on HF, HT @ Two Nation’s Leading HF & HT Centers
5.1.6 Endovascular Lower-extremity Revascularization Effectiveness: Vascular Surgeons (VSs), Interventional Cardiologists (ICs) and Interventional Radiologists (IRs)
5.1.7 Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care
5.1.8 AHA, ACC Change in Requirement for Surgical Support for PCI Performance: Class IIb -> Class III, Level of Evidence A: Support Nonemergent PCI without Surgical Backup (Change of class IIb, Level of evidence B)
5.1.9 Biomaterials Technology: Models of Tissue Engineering for Reperfusion and Implantable Devices for Revascularization
5.1.10 Vascular Repair: Stents and Biologically Active Implants
5.1.11 Regeneration: Cardiac System (cardiomyogenesis) and Vasculature (angiogenesis)
5.1.12 Fight against Atherosclerotic Cardiovascular Disease: A Biologics not a Small Molecule – Recombinant Human lecithin-cholesterol acyltransferase (rhLCAT) attracted AstraZeneca to acquire AlphaCore
5.1.13 Harnessing New Players in Atherosclerosis to Treat Heart Disease
5.2 The Role of Calcium in Health and Disease
5.2.1 Calcium Cycling (ATPase Pump) in Cardiac Gene Therapy: Inhalable Gene Therapy for Pulmonary Arterial Hypertension and Percutaneous Intra-coronary Artery Infusion for Heart Failure: Contributions by Roger J. Hajjar, MD – Part VI
5.2.2 Cardiac Contractility & Myocardium Performance: Ventricular Arrhythmiasand Non-ischemic Heart Failure – Therapeutic Implications for Cardiomyocyte Ryanopathy (Calcium Release-related Contractile Dysfunction) and Catecholamine Responses – Part VII
5.2.3 Calcium-Channel Blockers, Calcium Release-related Contractile Dysfunction (Ryanopathy) and Calcium as Neurotransmitter Sensor – Part IX
5.3 Conduction Dysfunction and ElectroPhysiology of the Heart
5.3.1 Cardiac Resynchronization Therapy (CRT) to Arrhythmias: Pacemaker/Implantable Cardioverter Defibrillator (ICD) Insertion
5.4 Cardiovascular Imaging: Diagnosing the Condition of the Disease and Determining Course of Treatment
5.4.1 3D Cardiovascular Theater – Hybrid Cath Lab/OR Suite, Hybrid Surgery, Complications Post PCI and Repeat Sternotomy
Leave a Reply